Live Breaking News & Updates on Jianzhong zhang

Stay updated with breaking news from Jianzhong zhang. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Kintor Pharma Announces 2022 Annual Results and Recent Business Progress

SUZHOU, China, March 30, 2023 /PRNewswire/ -- Kintor Pharmaceutical Limited (Kintor Pharma, HKEX: 9939), a clinical-stage biotechnology company de...

China , Hong-kong , Shanghai , Jishi , Guangdong , Gusu , Peking , Beijing , Suzhou , Jiangsu , Jilin , Chinese

Kintor Pharma says alopecia primary endpoint met

Kintor Pharma has announced results of a phase II clinical trial for its potential topical drug to treat adult female androgeneticalopecia.

Peking , Beijing , China , Kintor-pharma , Jianzhong-zhang , Kintor-pharmaceutical , Department-of-dermatology , University-people-hospital , Kintor-pharmaceutical-limited , Peking-university-people , Savin-scale ,

Kintor Pharma Announced the Primary Endpoint of Phase II Clinical Study for KX-826's Treatment of Female Androgenetic Alopecia in China Was Met

DJ Kintor Pharma Announced the Primary Endpoint of Phase II Clinical Study for KX-826's Treatment of Female Androgenetic Alopecia in China Was Met EQS Newswire / 02/12/2022 / 10:34 UTC+8 Kintor

China , Peking , Beijing , Suzhou , Jiangsu , Kintor-pharma , Jianzhong-zhang , Financial-press , Kintor-pharmaceutical , Department-of-dermatology , University-people-hospital , Kintor-pharmaceutical-limited-pharma

Kintor Announces 2022 Interim Results and Recent Business Update

/PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma" or "the Company", HKEX: 9939), a clinical-stage biotechnology company developing innovative...

China , Taiwan , United-states , Hong-kong , Suzhou , Jiangsu , Ghana , Guangdong , Jilin , Peking , Beijing , Sarajevo

Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Moderate-to-severe Plaque Psoriasis Met Primary Endpoint

Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Moderate-to-severe Plaque Psoriasis Met Primary Endpoint
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

China , Taiwan , United-states , Peking , Beijing , Hong-kong , Macau , Suzhou , Jiangsu , Chinese , Adimab-incyte , Jianzhong-zhang

Specialty Optical Fibers Based on 3D Printing Technology

Experiments with 3D printing of silica glasses and silica optical fiber performed have recently proven successful. One difficulty in 3D printing silica optical fibers is extending previous findings of small-scale glass “bulk or slice” print from very few millimeters to centimeters.

Xinghu-fu , Jing-ren , Yushi-chu , Jianzhong-zhang , Yanhua-luo , Jiaying-wang , D-printing-technology , University-of-new-south-wales , Research-sheds-light , Harbin-engineering-university , Sheds-light , Specialty-optical-fibers-based

Innovent Announces First Patient Dosed in a Phase 2 Clinical Trial of IBI112 (IL-23 Monoclonal Antibody) in Patients with Moderate-to-severe Plaque Psoriasis | Antibodies

Innovent Announces First Patient Dosed in a Phase 2 Clinical Trial of IBI112 (IL-23 Monoclonal Antibody) in Patients with Moderate-to-severe Plaque Psoriasis | Antibodies
pipelinereview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pipelinereview.com Daily Mail and Mail on Sunday newspapers.

China , United-states , Peking , Beijing , Hong-kong , Suzhou , Jiangsu , Chinese , Innovent-biologics , Adimab-incyte , Jianzhong-zhang , Eli-lilly

Innovent Announces First Patient Dosed in a Phase 2 Clinical Trial of IBI112 (IL-23 Monoclonal Antibody) in Patients with Moderate-to-severe Plaque Psoriasis

/PRNewswire/ -- Innovent Biologics, Group. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

China , Taiwan , United-states , Peking , Beijing , Hong-kong , Macau , Suzhou , Jiangsu , Chinese , Adimab-incyte , Jianzhong-zhang

Reistone Announces Positive Topline Phase 2 Results for SHR0302, a Selective JAK1 Inhibitor, for Treatment of Patients with Alopecia Areata

Reistone Announces Positive Topline Phase 2 Results for SHR0302, a Selective JAK1 Inhibitor, for Treatment of Patients with Alopecia Areata
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Australia , Shanghai , China , United-states , Boston , Massachusetts , Beijing , Peking , Chicago , Illinois , Aik-han-goh , Qais-mekki